{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
mafodotin
to a specific field?
There is one exact (name or code) match for mafodotin
Status:
Investigational
Source:
USAN:MAFODOTIN [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Mafodotin (mc-MMAF) is a hydrophilic non-cleavable antimicrotubule and antimitotic agent, monomethyl auristatin F (MMAF) derivative, having a maleimidocaproyl linker (mc linker), which is ready to conjugate to an antibody or other proteins or biopolymers. Antibody-drug conjugates having mafodotin such as Depatuxizumab mafodotin and Belantamab mafodotin have undergone clinical trials for the treatment of neoplasms.
Status:
Investigational
Source:
USAN:MAFODOTIN [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Mafodotin (mc-MMAF) is a hydrophilic non-cleavable antimicrotubule and antimitotic agent, monomethyl auristatin F (MMAF) derivative, having a maleimidocaproyl linker (mc linker), which is ready to conjugate to an antibody or other proteins or biopolymers. Antibody-drug conjugates having mafodotin such as Depatuxizumab mafodotin and Belantamab mafodotin have undergone clinical trials for the treatment of neoplasms.
Status:
Investigational
Source:
JAN:DEPATUXIZUMAB MAFODOTIN [JAN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03849651: Phase 2 Interventional Active, not recruiting Acute Lymphoblastic Leukemia (ALL)
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03455972: Phase 1/Phase 2 Interventional Unknown status Safety and Efficacy
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03428022: Phase 3 Interventional Unknown status NSCLC
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
USAN:DENINTUZUMAB [USAN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:denintuzumab mafodotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
